Vanda Pharmaceuticals Inc.
VNDAHealthcareNASDAQBiotechnology · Last scanned Jun 1, 2026
Scan Results
Daily timeframePart of the healthcare sector, Vanda Pharmaceuticals Inc. (VNDA) is listed under Biotechnology. With a market capitalization of $387.9M, it sits in small-cap territory. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Market Cap
$387.9M
Beta
0.65
P/E (TTM)
—
P/E (Fwd)
32.25
EPS (TTM)
$-4.06
EPS (Fwd)
$0.20
ROE
-60.5%
ROA
-18.8%
Cash
$202.3M
Total Debt
$13.1M
Free CF
-$83.2M
52W Change
50.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $202.3M in cash comfortably exceeding the $13.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$83.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -60.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $254.4M to $216.1M.
VNDA's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, VNDA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VNDA.